InsidersTradesSigma
Follow the 인바디 share price and the full management transaction log of the company, a listed issuer based in South Korea. Shares are quoted on the KR market, under the oversight of DART (FSS). Operating in the Health Care sector, 인바디 has recorded 34 insider filings. Market capitalisation: €923.2bn. The latest transaction was filed on 3 July 2026 (Purchase). Among the most active insiders: 차인준. Every trade is accessible without an account.
32
Insider Decl.
n/a
Thresholds
n/a
9 ops.
Buy Volume
n/a
2 ops.
Sell Volume
Analyst consensus: bullish or bearish?
Analysts rate 인바디 Buy (bullish), based on 1 analysts. Average price target: ₩100,000.
23Σ signal
This score ranks the purchase within its own market. No market currently meets the historical allocation criteria, so signals remain watch-only. Not investment advice.
Fundamental score
Ranked 5,834 of 28,753 companies
66.6
score / 100
Value49
Quality84
FCF yld3.6%
Earn yld3.8%
EV/EBITDA16.9x
ROE·
Gross mgn77%
Net mgn13%
Debt/EBITDA0.2x
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
AI analysis generation is paused.
Last declaration on 3 July 2026
Declarations34 total
Other
Other
149,804 sharesKRXDART:20260428000253
25 of 34 declarations
About 인바디
InBody is a company specializing in the development of body composition measurement technologies. It is listed on the XKRX market.